3. Supplemental financial information

Cash, cash equivalents and restricted cash

Cash and cash equivalents consist of cash and, if applicable, highly liquid investments with an original maturity of three months or less when purchased. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the condensed statements of cash flows (amounts in thousands).


	As of		As of
	September 30,		December 31,
	2019		2018
Cash and cash equivalents	$	114,214	$	150,637
Short-term and long-term restricted cash		345		491
Total cash, cash equivalents, and restricted cash shown in the statements of cash flows	$	114,559	$	151,128

Prepaid expenses and other current assets

Prepaid expenses and other current assets consist of the following (in thousands):


	As of		As of
	September 30,		December 31,
	2019		2018
Prepaid clinical	$	1,970	$	728
Prepaid insurance		1,220		673
Prepaid manufacturing costs		435		—
Other prepaid expenses and current assets		355		383
Total prepaid expenses and other current assets	$	3,980	$	1,784

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):


	As of		As of
	September 30,		December 31,
	2019		2018
Employee-related expenses	$	1,954	$	2,043
Development costs and sponsored research		1,746		915
Clinical trials		1,176		607
Professional services		125		211
Other		343		220
Total accrued expenses and other current liabilities	$	5,344	$	3,996